radical cystectomy
Recently Published Documents


TOTAL DOCUMENTS

6941
(FIVE YEARS 1836)

H-INDEX

114
(FIVE YEARS 13)

2022 ◽  
Vol 36 ◽  
pp. 34-40
Author(s):  
Etienne Lavallée ◽  
Zach Dovey ◽  
Prachee Pathak ◽  
Linda Dey ◽  
Lotta Renström Koskela ◽  
...  

Uro ◽  
2022 ◽  
Vol 2 (1) ◽  
pp. 6-12
Author(s):  
Francesco Cianflone ◽  
Alberto Bianchi ◽  
Giovanni Novella ◽  
Alessandro Tafuri ◽  
Maria Angela Cerruto ◽  
...  

In localized muscle invasive bladder cancer (MIBC), the gold standard treatment is radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND), associated with cisplatin-based neoadjuvant chemotherapy, whereas first-line treatment for metastatic patients is cisplatin-based chemotherapy. In men with an abdominal aortic aneurysm (AAA), elective repair is recommended when its diameter is >5.5 cm, while cryopreserved arterial allografts (CAA) offer resistance to infection. A patient with simultaneous metastatic MIBC, associated with left hydronephrosis, and infrarenal AAA of 49 mm diameter was evaluated in an interdisciplinary study. Concomitant surgery was opted for; first, the AAA repair with CAA implantation was practiced, followed by retroperitoneal and common iliac lymphadenectomy. Thereafter, RC and PLND were conducted, and a Wallace-1 ileal conduit and a stoma were constructed. Chest and abdomen contrast-enhanced CT at 2 months showed the onset of two osteolytic lesions on the left ilium. At oncological re-evaluation the patient was deemed cisplatin-fit.


2022 ◽  
Author(s):  
Dai Koguchi ◽  
Kazumasa Matsumoto ◽  
Masaomi Ikeda ◽  
Yoshinori Taoka ◽  
Takahiro Hirayama ◽  
...  

Abstract Background In patients experiencing disease recurrence after radical cystectomy (RC) for bladder cancer, data about the impact of clinicopathologic factors, including salvage treatment using cytotoxic chemotherapy, on the survival are scarce. We investigated the prognostic value of clinicopathologic factors and the treatment effect of salvage cytotoxic chemotherapy (SC) in such patients. Methods In this retrospective study, we evaluated the clinical data for 86 patients who experienced recurrence after RC. Administration of SC or of best supportive care (BSC) was determined in consultation with the urologist in charge and in accordance with each patient’s performance status, wishes for treatment, and renal function. Statistical analyses explored for prognostic factors and evaluated the treatment effect of SC compared with BSC in terms of cancer-specific survival (CSS). Results Multivariate analyses showed that liver metastasis after RC (hazard ratio [HR]: 2.13; 95% confidence interval [CI]: 1.17 to 3.85; P = 0.01) and locally advanced disease at RC (HR: 1.92; 95% CI: 1.06 to 3.46; P = 0.03) are independent risk factors for worse CSS in patients experiencing recurrence after RC. In a risk stratification model, patients were assigned to one of two groups based on liver metastasis and locally advanced stage. In the high-risk group, which included 68 patients with 1–2 risk factors, CSS was significantly better for patients receiving SC than for those receiving BSC (median survival duration: 9.4 months vs. 2.4 months, P = 0.005). The therapeutic effect of SC was not related to a history of adjuvant chemotherapy. Conclusions The present study indicated the potential value of 1st-line SC in patients experiencing recurrence after RC even with advanced features, such as liver metastasis after RC and locally advanced disease at RC.


2022 ◽  
Vol 48 (1) ◽  
pp. 89-98
Author(s):  
Lennert Eismann ◽  
Severin Rodler ◽  
Alexander Tamalunas ◽  
Gerald Schulz ◽  
Friedrich Jokisch ◽  
...  

Urology ◽  
2022 ◽  
Author(s):  
Matvey Tsivian ◽  
Raevti Bole ◽  
Vignesh T Packiam ◽  
Stephen A Boorjian ◽  
Prabin Thapa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document